Jazz Pharmaceuticals PLC at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
All right. Thanks, everyone, for joining us. I'm Dan Busby, the pharmaceuticals analyst at RBC Capital Markets. And our next company presenting today is Jazz Pharmaceuticals. You are just 2 weeks removed from the close of the company's GW Pharmaceuticals acquisition, so it's a very opportune time to have a conversation.
I'm joined this morning by Jazz Chairman and CEO, Bruce Cozadd, former GW Pharma CEO, Justin Gover; Dan Swisher, President; and Rob Iannone, EVP, R&D and Chief Medical Officer. Bruce, before we jump into Q&A, I'd like to give you the opportunity to provide some brief opening comments.
Jazz is a very different company today than it was just a few years ago. So where do we stand in the company's transformation? And what's still to come?
Yes, Dan, thanks for the opportunity to be here. And you're right. We are a different company from a few years ago. I'd say we're a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |